Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections

Seuchi Aonuma; Kotaro Oizumi; Akira Watanabe; Masakichi Motomiya; Kiyoshi Konno; Kosaku Nagai

doi:10.11250/chemotherapy1953.37.Supplement3_214

Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections

Seuchi Aonuma, Kotaro Oizumi, Akira Watanabe, Masakichi Motomiya, Kiyoshi Konno, Kosaku Nagai

Research output: Contribution to journal › Article › peer-review

Abstract

We examined the in vitro antimicrobial activity of BMY-28100, a newly developed cephem antibiotic, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of BMY-28100 against 120 clinical isolates were compared with those of cefaclor (CCL) and cefixime (CFIX). Against Staphylococcus aureus, BMY-28100 was much more active than CCL and CFIX, but against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae and Pseudomonas aeruginosa, it was as active as CCL and much less active than CFIX. Twelve patients suffering from respiratory tract infection received orally 750mg or 1000mg of BMY-28100 a day. Clinical response was excellent in 1, good in 7, fair in 1 and poor in 3 patients. Mild anemia was observed in one patient.

Original language	English
Pages (from-to)	214-221
Number of pages	8
Journal	Chemotherapy
Volume	37
DOIs	https://doi.org/10.11250/chemotherapy1953.37.Supplement3_214
Publication status	Published - 1989 Jan 1

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.37.Supplement3_214

Cite this

@article{b58beb9852194ac892393ef946b12802,

title = "Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections",

abstract = "We examined the in vitro antimicrobial activity of BMY-28100, a newly developed cephem antibiotic, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of BMY-28100 against 120 clinical isolates were compared with those of cefaclor (CCL) and cefixime (CFIX). Against Staphylococcus aureus, BMY-28100 was much more active than CCL and CFIX, but against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae and Pseudomonas aeruginosa, it was as active as CCL and much less active than CFIX. Twelve patients suffering from respiratory tract infection received orally 750mg or 1000mg of BMY-28100 a day. Clinical response was excellent in 1, good in 7, fair in 1 and poor in 3 patients. Mild anemia was observed in one patient.",

author = "Seuchi Aonuma and Kotaro Oizumi and Akira Watanabe and Masakichi Motomiya and Kiyoshi Konno and Kosaku Nagai",

year = "1989",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.37.Supplement3_214",

language = "English",

volume = "37",

pages = "214--221",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections

AU - Aonuma, Seuchi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Motomiya, Masakichi

AU - Konno, Kiyoshi

AU - Nagai, Kosaku

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We examined the in vitro antimicrobial activity of BMY-28100, a newly developed cephem antibiotic, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of BMY-28100 against 120 clinical isolates were compared with those of cefaclor (CCL) and cefixime (CFIX). Against Staphylococcus aureus, BMY-28100 was much more active than CCL and CFIX, but against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae and Pseudomonas aeruginosa, it was as active as CCL and much less active than CFIX. Twelve patients suffering from respiratory tract infection received orally 750mg or 1000mg of BMY-28100 a day. Clinical response was excellent in 1, good in 7, fair in 1 and poor in 3 patients. Mild anemia was observed in one patient.

AB - We examined the in vitro antimicrobial activity of BMY-28100, a newly developed cephem antibiotic, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of BMY-28100 against 120 clinical isolates were compared with those of cefaclor (CCL) and cefixime (CFIX). Against Staphylococcus aureus, BMY-28100 was much more active than CCL and CFIX, but against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae and Pseudomonas aeruginosa, it was as active as CCL and much less active than CFIX. Twelve patients suffering from respiratory tract infection received orally 750mg or 1000mg of BMY-28100 a day. Clinical response was excellent in 1, good in 7, fair in 1 and poor in 3 patients. Mild anemia was observed in one patient.

UR - http://www.scopus.com/inward/record.url?scp=0024930847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024930847&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.37.Supplement3_214

DO - 10.11250/chemotherapy1953.37.Supplement3_214

M3 - Article

AN - SCOPUS:0024930847

SN - 0009-3165

VL - 37

SP - 214

EP - 221

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this